Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...

Wānaka resident and multiple myeloma blood cancer patient Emma Holden, 36, will soon travel to Shanghai, China for ...

City of Hope® Research Spotlight offers a glimpse at groundbreaking scientific and clinical discoveries advancing lifesaving cures for patients with cancer, diabetes and other chronic, ...

Therapy timing, patient factors, and emerging combination interventions are guiding treatment decisions in multiple myeloma and lymphoma.

Medically reviewed by Marla Anderson, MD Multiple myeloma is a rare type of blood cancer that starts in your plasma cells.

Genetic testing should be used to help doctors spot high-risk cases of myeloma and enable targeted treatments, say researchers from the University of Leeds and The Institute of Cancer Research.

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

The FDA granted orphan drug designation to OPN-6602 for the potential treatment of relapsed/refractory multiple myeloma. The FDA granted orphan drug designation (ODD) to OPN-6602 for the treatment of ...

It's combined with bendamustine, a chemotherapy drug that damages cancer cell DNA, and rituximab, an immunotherapy drug that targets and kills cancerous B cells. Both are given through an IV and ...

Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood cells that produce infection-fighting antibodies. Multiple myeloma is not hereditary, meaning it is not passed ...